Overall, these results validated the RPPA results and supported (1) the selective downregulation of phospho-S6 and phospho-4E-BP1 by Dactolisib in Gr-MDSCs and PCa cells, and (2) the preferential downregulation of phospho-Src and phospho-p38 MAPK by Dasatinib in T cells. The gene discussed is EIF4EBP1; the disease is posterior cortical atrophy.